NASDAQ:AEMD

Aethlon Medical Stock Forecast, Price & News

$4.90
+0.03 (+0.62 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.82
$5.10
50-Day Range
$1.69
$10.79
52-Week Range
$1.22
$12.49
Volume310,331 shs
Average Volume1.75 million shs
Market Capitalization$75.36 million
P/E RatioN/A
Dividend YieldN/A
Beta0.65
30 days | 90 days | 365 days | Advanced Chart
Receive AEMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Aethlon Medical and its competitors with MarketBeat's FREE daily newsletter.


Aethlon Medical logo

About Aethlon Medical

Aethlon Medical, Inc. is a medical technology company, which focuses on developing products to diagnose and treat life and organ threatening diseases. It develops Aethlon Hemopurifier, which is a clinical-stage immunotherapeutic device designed to combat cancer and life-threatening viral infections. The firm operates through the following segments: Aethlon and ESI. The Aethlon segment involves in therapeutic business activities. The ESI segment consists of diagnostic business activities. The company was founded by James A. Joyce in 1991 and is headquartered in San Diego, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.78 out of 5 stars

Medical Sector

809th out of 2,220 stocks

Surgical & Medical Instruments Industry

86th out of 185 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Aethlon Medical (NASDAQ:AEMD) Frequently Asked Questions

Is Aethlon Medical a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aethlon Medical in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Aethlon Medical stock.
View analyst ratings for Aethlon Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Aethlon Medical?

Wall Street analysts have given Aethlon Medical a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Aethlon Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Aethlon Medical?

Aethlon Medical saw a drop in short interest in July. As of July 15th, there was short interest totaling 200,400 shares, a drop of 30.1% from the June 30th total of 286,500 shares. Based on an average daily volume of 5,780,000 shares, the days-to-cover ratio is presently 0.0 days.
View Aethlon Medical's Short Interest
.

When is Aethlon Medical's next earnings date?

Aethlon Medical is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Aethlon Medical
.

How can I listen to Aethlon Medical's earnings call?

Aethlon Medical will be holding an earnings conference call on Monday, August 9th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "10159282".

How were Aethlon Medical's earnings last quarter?

Aethlon Medical, Inc. (NASDAQ:AEMD) announced its quarterly earnings data on Wednesday, June, 23rd. The medical equipment provider reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.05. The medical equipment provider had revenue of $0.03 million for the quarter, compared to analysts' expectations of $0.46 million.
View Aethlon Medical's earnings history
.

How has Aethlon Medical's stock price been impacted by COVID-19 (Coronavirus)?

Aethlon Medical's stock was trading at $1.99 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AEMD stock has increased by 146.2% and is now trading at $4.90.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AEMD?

2 brokerages have issued 1 year target prices for Aethlon Medical's stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate Aethlon Medical's stock price to reach $10.00 in the next year. This suggests a possible upside of 104.1% from the stock's current price.
View analysts' price targets for Aethlon Medical
or view top-rated stocks among Wall Street analysts.

Who are Aethlon Medical's key executives?

Aethlon Medical's management team includes the following people:
  • Charles J. Fisher, Chief Executive Officer & Director
  • James B. Frakes, Chief Financial & Principal Accounting Officer
  • Annette Marleau, Research Director
  • Steven LaRosa, Chief Medical Officer
  • Guy F. Cipriani, Director, Chief Business Officer & Senior VP

Who are some of Aethlon Medical's key competitors?

What other stocks do shareholders of Aethlon Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aethlon Medical investors own include Amarin (AMRN), Nokia (NOK), Vaxart (VXRT), VBI Vaccines (VBIV), Nabriva Therapeutics (NBRV), CRISPR Therapeutics (CRSP), Novavax (NVAX), OrganiGram (OGI), AT&T (T) and Aurora Cannabis (ACB).

What is Aethlon Medical's stock symbol?

Aethlon Medical trades on the NASDAQ under the ticker symbol "AEMD."

How do I buy shares of Aethlon Medical?

Shares of AEMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aethlon Medical's stock price today?

One share of AEMD stock can currently be purchased for approximately $4.90.

How much money does Aethlon Medical make?

Aethlon Medical has a market capitalization of $75.36 million and generates $660,000.00 in revenue each year. The medical equipment provider earns $-7,890,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How many employees does Aethlon Medical have?

Aethlon Medical employs 8 workers across the globe.

What is Aethlon Medical's official website?

The official website for Aethlon Medical is www.aethlonmedical.com.

Where are Aethlon Medical's headquarters?

Aethlon Medical is headquartered at 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123.

How can I contact Aethlon Medical?

Aethlon Medical's mailing address is 9635 GRANITE RIDGE DRIVE SUITE 100, SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at (858) 459-7800 or via email at [email protected]


This page was last updated on 8/1/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.